Running Decentralized Trials At Scale: Planning For Success

The COVID-19 pandemic accelerated the adoption of decentralized clinical trials (DCTs), driving the rapid expansion of virtual tools designed to support remote patient participation and trial management. As the industry continues to embrace decentralized approaches, sponsors are recognizing the potential benefits of DCTs, including reduced operational costs and improved recruitment and retention of more diverse patient populations. However, successfully launching and scaling decentralized trials requires careful planning across both clinical and supply chain functions, with protocols that clearly define evolving roles and responsibilities. Sponsors must also address challenges related to sustained patient engagement, shipping and logistics, process consistency, and compliance with varying state and international regulations.